Stockreport

FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF ductal adenocarcinoma and, in June 2025, received US FDA Breakthrough Therapy Designation for previously treated patients with KRAS G12-mutant disease. This regulatory [Read more]